Masimo MASI announced today FDA 510(k) clearance and CE Mark of its new Radical-7® with rainbow® Acoustic Monitoring capability for continuous display of the acoustic respiration rate (RRa™) waveform and measurements. Also new to the Radical-7 is an In Vivo Adjustment™ (pending FDA 510(k) clearance in the U.S.) that allows clinicians to, for the first time, adjust the noninvasive measurements to the specific patient and laboratory reference device they use for invasive blood testing.
MASIMasimo Corp
$169.352.36%
Edge Rankings
Momentum93.11
Growth56.58
Quality-
Value17.85
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in